Health
-
Forget the Posturing – The Inflation Reduction Act May Work Better Than Many Expected
Aug 16, 2024
The IRA has the potential to rectify the imbalance between public benefit and private incentives
-
Crying Wolf: Why Negotiating Lower Drug Prices Will Not Harm Pharmaceutical Innovation
Jul 22, 2024
Increasing evidence that the IRA is probably not harming pharmaceutical innovation.
-
Working Paper
Implications of the Inflation Reduction Act for the Biotechnology Industry
Jul 2024
Sensitivity of investment and valuation to drug price indices and market conditions
-
Expert: Why Covid and Future Pandemics are a Bigger Threat than Nukes
Jul 18, 2024
Dr. Phillip Alvelda tells INET’s Lynn Parramore about persistent political and public health failures exposing us to devastating diseases, while vastly underestimating their long-term health effects.
-
“Debilitating a Generation”: Expert Warns That Long COVID May Eventually Affect Most Americans
Jun 13, 2024
In a candid discussion with INET’s Lynn Parramore, Dr. Phillip Alvelda highlights the imminent dangers of long COVID, criticizing governments and health agencies for ongoing preventable suffering and deaths. *This is Part 2 of a two-part interview.
-
From Long COVID Odds to Lost IQ Points: Ongoing Threats You Don’t Know About
May 31, 2024
Stuck in a fog of misleading narratives, most of us don’t see the true extent of COVID’s persisting—and intensifying—threats. INET’s Lynn Parramore talks to Dr. Phillip Alvelda about the dangers we’re missing and the failures of public health agencies to inform and protect us. *This is Part 1 of a two-part interview.
-
Work Longer, Die Sooner! America's Dire Need to Expand Social Security and Medicare
May 8, 2024
Experts are clear that working into old age often threatens the health and well-being of U.S. seniors.
-
Resolving Global Vaccine Inequity
ConferenceInnovation, Capabilities and Governance
Apr 11–12, 2024
The development of COVID-19 vaccines within a year of the emergence of SARS-CoV-2 was an unprecedented triumph of scientific research that saved millions of lives. In contrast, the lack of global coordination to manage intellectual property, technology transfer, production, financing, and distribution of vaccines led to excess deaths and losses in economic output.
-
The Global Pharmaceutical Industry Isn’t Investing in Products for the Greatest Burden of Human Disease - Are Non-Profits a Solution?
Mar 29, 2024
Programs for expedited review may be preferentially reducing the development costs for conditions with lesser disease burden, potentially making investments in addressing the most significant disease burdens even less appealing and exacerbating the market failure further.
-
Experts: Negotiating Big Pharma's Prices Won't Stifle Innovation—They Don't Use the Money to Innovate!
Mar 14, 2024
Industry lobbyists vehemently oppose Medicare drug price negotiations. However, physician-scientist Fred Ledley and economist William Lazonick debunk their arguments.
-
How Should the Government Negotiate Medicare Drug Prices? A Guide for the Perplexed
Mar 4, 2024
The “maximum fair price” for a drug must not only be equitable to those with unmet medical needs who may benefit from the use of the drug but also provide equitable returns on both public and private sector investments.
-
Working Paper
Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis
Mar 2024
The empirical analysis of public sector investments and the health value created by the drugs selected for Medicare price negotiations provides a cost basis for the assessment of the maximum fair price.
-
What Has the World Learned from COVID-19? So Far, Not Nearly Enough
Sep 12, 2023
By all accounts infection rates have ebbed. But were we good or were we lucky?
-
ER Doctor: "Private Equity in Medicine is Dangerous to Patients"
Jun 22, 2023
Dr. Ming Lin, and healthcare providers like him, are fighting to take back control of medicine from private equity firms that are gobbling up practices and facilities. Should Wall Street make life-and-death decisions based on the bottom line?
-
Working Paper
What Next for the Post Covid Global Economy: Could Negative Supply Shocks Disrupt Other Fragile Systems?
Jan 2023
The principal threat to economic stability currently is the overhang of debt, both private and public.